The role of chemokines in human immunodeficiency virus infection

Immunological Reviews

Volumn 177, Issue , 2000, Pages 79-87

  Garzino Demo, Alfredo ^a,b   DeVico, Anthony L ^a,b   Conant, Katherine E ^b   Gallo, Robert C ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTROCYTE; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; MONOCYTE; PRIORITY JOURNAL; REVIEW;

EID: 0033647215     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2000.17711.x     Document Type: Review

References (83)

1. + T cells
2. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor
3. CC-CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
4. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
5. Identification of a major co-receptor for primary isolates of HIV-1
6. + T cells is mediated by the chemokine receptor CC-CKR-5
7. A dual tropic primary isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2B as fusion cofactors
8. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
9. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
10. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
11. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
12. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
13. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor-5-studies in populations with contrasting clinical phenotypes, defined racial backgrounds, and quantified risk
14. + T cell anti-HIV activity correlates with the clinical state of the infected individual
15. C-C chemokines, pivotal in protection against HIV type 1 infection
16. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status
17. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure
18. + lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of β-chemokines
19. Protective role of β-chemokines associated with HIV-specific Th responses against perinatal HIV transmission
20. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro
21. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection
22. + T cell responses associated with control of viremia
23. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: Effect of potent antiretroviral therapy
24. Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS
25. + T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele
26. Production of β-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1β are associated with a decreased risk of HIV disease progression
27. Increased intracellular accumulation of macrophage inflammatory protein 1β and its decreased secretion correlate with advanced HIV disease
28. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication
29. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques
30. Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques
31. Generation of CD8 suppressor factor and β chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques
32. β-Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques
33. β-Chemokines in macaques vaccinated with live attenuated virus correlates with protection against SIV(5m) challenge
34. Kinetics of β-chemokine levels during anti-HIV therapy
35. Change in circulating levels of the chemokines macrophage inflammatory proteins 1α and 11β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir
36. β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans
37. Antigen-specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytes
38. + T cells during an acute virus infection
39. + T cell clones during primary HIV infection
40. Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus
41. + patients produce C-C chemokines and inhibit HIV-1 infection
42. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro
43. Inhibition of HIV-1 infection by the β-chemokine MDC
44. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction
45. Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine
46. Sensitivity of human immunodeficiency virus infection to various α, β and γ chemokine
47. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells
48. Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes
49. Do β-chemokines have clinical relevance in HIV infection?
50. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage
51. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor
52. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection
53. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage
54. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV
55. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity
56. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction
57. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity
58. Two inflammatory mediator cytokine genes are closely linked and variably amplified on chromosome 17q
59. Structures of human genes coding for cytokine LD78 and their expression
60. Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans
61. 2+ signaling
62. The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state
63. Tyrosine sulfation of the amino terminus of CCR-5 facilitates HIV-1 entry
64. Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1α, MIP-1β and RANTES β-chemokines
65. + T cells: Role of signal transduction
66. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion
67. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5
68. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages
69. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4
70. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry
71. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice
72. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia
73. β-Chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia
74. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication
75. The human immunodeficiency virus type 1 Tat protein up-regulates the promoter activity of the β-chemokine monocyte chemoattractant protein 1 in the human astrocytoma cell line U-87 MG: Role of SP-1, AP-1, and NF-κB consensus sites
76. Temporal and spatial patterns of c-fos mRNA induced by intravenous interleukin-1: A cascade of non-neuronal cellular activation at the blood-brain barrier
77. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1
78. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
79. Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: Effects on chemokine production
80. Heat shock proteins generate β-chemokines which function as innate adjuvants enhancing adaptive immunity
81. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques
82. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro
83. Strategies for AIDS vaccines